Purpose Alpha-fetoprotein (AFP) is considered to be an indicator of tumor activity in
hepatocellular carcinoma (HCC). We present a novel correlation of AFP response to …

Purpose There are limitations in using radiologic evaluation to assess the treatment
outcome of patients with hepatocellular carcinoma (HCC). The use of serial α-fetoprotein …

Background. The role of serum α-fetoprotein (AFP) as a marker for treatment response in
patients with hepatocellular carcinoma (HCC) receiving systemic therapy is poorly defined …

BACKGROUND & AIMS: Alpha-fetoprotein (AFP) is a universally recognized tumor marker in
hepatocellular carcinoma (HCC). Its utility in assessing response to treatment remains …

Backgrounds: There are limitations in using only radiological criteria to evaluate treatment
outcomes in hepatocellular carcinoma (HCC). α‐fetoprotein (AFP) is regarded as an …

BACKGROUND: Antiangiogenic therapy has become the most important treatment modality
for patients with advanced hepatocellular carcinoma (HCC). In this study, the authors …

Background: Post-treatment alpha-fetoprotein (AFP) response has been reported to be
associated with prognosis of hepatocellular carcinoma (HCC) patients, but the results were …

Background Alpha-fetoprotein (AFP) has been used as a diagnostic biomarker for
hepatocellular carcinoma (HCC), but its prognostic significance is not well defined. This …

Background We evaluated treatment modalities and survival in patients with hepatocellular
carcinoma (HCC), by pre-treatment and 3-month post-treatment serum alpha-fetoprotein …

OBJECTIVES To assess, in a large multi-centric survey, diagnostic and prognostic reliability
of AFP, predictive factors, and any correlation with the tumor immunophenotype. METHODS …